Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

NCT06959979 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Medulloblastoma, Childhood

Interventions

DRUG: CDK4/6 Inhibitor (Palbociclib, Ribociclib, Abemaciclib)

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborators

[object Object]
[object Object]
[object Object]